Skip to main content

Table 1 Prevalence of NTRK gene fusions in solid tumors

From: Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Tumor type

Prevalence

References

Appendiceal

0.56%–2%

Braghiroli et al. 2016 [36]; Forsythe et al. 2020 [37]

Cholangiocarcinoma

4%

Ross et al. 2014 [38]

Colorectal

0.2%–0.5%

Gatalica et al. 2019 [7]; Creancier et al. 2015 [39]; Forsythe et al. 2020 [37]

Glioblastoma

3%

Zheng et al. 2014 [40]

High-grade glioma

21.21%

Forsythe et al. 2020 [37]

High-grade glioma, pediatric

5.3%–6.19%

Forsythe et al. 2020 [37]; Okamura et al. 2018 [41]

Head and neck cancer

0.5%

Stransky et al. 2014 [12]

Infantile fibrosarcoma

70%–91%

Amatu et al. 2019 [2]; Vaishnavi et al. 2015 [9]; Forsythe et al. 2020 [37]

Low-grade glioma

0.4%–0.88%

Stransky et al. 2014 [12]; Forsythe et al. 2020 [37]

Low-grade glioma, pediatric

1.61%

Forsythe et al. 2020 [37]

Lung adenocarcinoma

0.1%

Gatalica et al. 2019 [7]; Farago et al. 2015 [42]; Forsythe et al. 2020 [37]

Melanoma

0.3%

Stransky et al. 2014 [12]; Forsythe et al. 2020 [37]

Papillary thyroid carcinoma

 < 5%–25%

Brzezianska et al. 2006 [43]; Greco et al. 2010 [44]; Wajjwalku et al. 1992 [45]; Said et al. 1994 [46]; Butti 1995 [47]; Delvincourt et al. 1996 [48]; Bounacer et al. 2000 [49]; Forsythe et al. 2020 [37]

Pilocytic astrocytoma

3%

Jones et al. 2013 [50]

Secretory breast carcinoma

92.87%

Tognon et al. 2002 [51]; Forsythe et al. 2020 [37]

Secretory carcinoma of salivary gland

66%–93%

Skalova et al. 2014 [52]; Skalova et al. 2010 [53]; Forsythe et al. 2020 [37]

Soft tissue sarcoma

(non-infantile fibrosarcoma)

 < 5%

Demetri et al. 2020 [55]

Spitzoid melanoma

16%

Wiesner et al. 2014 [54]